聚乙二醇干扰素α-2b与利巴韦林治疗丙型肝炎病毒相关性混合性冷球蛋白血症：一项初步研究。
Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
作者信息
Mazzaro Cesare, Zorat Francesca, Caizzi Manuela, Donada Carlo, Di Gennaro Giampiero, Maso Luigino Dal, Carniello Giorgio, Virgolini Luigi, Tirelli Umberto, Pozzato Gabriele
机构信息
Department of Internal Medicine, Pordenone General Hospital, Via Montereale 24, 33170 Pordenone (PN), Italy.
出版信息
J Hepatol. 2005 May;42(5):632-8. doi: 10.1016/j.jhep.2004.10.031.
BACKGROUND/AIMS: The aim of this study is to verify the efficacy and safety of peg-interferon alfa-2b in combination with ribavirin for initial treatment of HCV-associated mixed cryoglobulinemia.
METHODS
Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 microg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype.
RESULTS
At the end of the treatment HCV-RNA became undetectable in 15 patients (83%) and most patients improved clinically. One subject suspended treatment at 13th week due to depression. A large fraction of the patients (8 cases: 44%) relapsed both virologically and clinically a few weeks after the end of therapy. At the end of follow-up, only eight patients (44%) obtained a sustained virological response.
CONCLUSIONS
Peg-interferon alfa-2b in combination with ribavirin seems safe and useful for patients affected by mixed cryoglobulinemia, but not as effective as in patients with HCV-positive chronic hepatitis without cryoglobulinemia.
背景/目的：本研究旨在验证聚乙二醇干扰素α-2b联合利巴韦林用于初治丙型肝炎病毒（HCV）相关混合性冷球蛋白血症的疗效和安全性。
方法
18例混合性冷球蛋白血症患者（7例女性，11例男性）纳入本研究，接受聚乙二醇干扰素α-2b 1.0μg/kg每周1次联合利巴韦林（每日1000mg）治疗48周，不考虑HCV基因型。
结果
治疗结束时，15例患者（83%）HCV-RNA检测不到，且多数患者临床症状改善。1例患者因抑郁于第13周中断治疗。很大一部分患者（8例：44%）在治疗结束后几周出现病毒学和临床复发。随访结束时，仅8例患者（44%）获得持续病毒学应答。
结论
聚乙二醇干扰素α-2b联合利巴韦林对混合性冷球蛋白血症患者似乎安全有效，但不如对无冷球蛋白血症的HCV阳性慢性肝炎患者有效。
Zotero 插件